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Objective: Surgery alone remains the standard therapy for patients with stage I non–
small cell lung cancer. Although the preoperative serum level of carcinoembryonic
antigen has been shown to be an independent prognostic factor, it has not yet been
included in the staging system and does not alter the treatment strategy, especially
in the selection of patients for adjuvant chemotherapy.
Methods: From 1986 to 2003, preoperative and postoperative serum carcinoem-
bryonic antigen levels were measured in 455 patients with completely resected path-
ologic stage I non–small cell lung cancer. We compared the clinicopathologic
characteristics and outcomes among patients who had preoperative serum carcinoem-
bryonic antigen levels within the normal range (N group, n5 323), patients who had
high carcinoembryonic antigen levels before surgery but normal levels after surgery
(HN group, n 5 112), and patients who had high carcinoembryonic antigen levels
before and after surgery (HH group, n 5 20).
Results: The significant characteristics of the HN group included the male sex, greater
age, smoking, squamous cell histology, T2 status, lymphatic invasion, vascular inva-
sion, and pleural invasion. Adenocarcinomas in patients of the HN group were more
likely to be moderately to poorly differentiated. The 5-year survivals in the HN and
HH groups were significantly lower (56.2% and 43.1%, respectively) than those in
the N group (85.9%). Multivariate analysis revealed that greater age, non-adenocar-
cinoma histology, pleural invasion, and the carcinoembryonic antigen in the HN
and HH groups were independent prognostic factors.
Conclusion: Patients with resected pathologic stage I non–small cell lung cancer and
high preoperative serum carcinoembryonic antigen levels are a subgroup with a dis-
tinctly poor prognosis who display smoking-related clinicopathologic characteristics.
R
ecent randomized controlled trials have shown a survival benefit from adju-
vant chemotherapy in patients with stage II or more advanced non–small
cell lung cancer (NSCLC),1-3 whereas surgery alone remains the standard
therapy for patients with stage I disease. However, it has been thought that there is
a subgroup of patients with stage I NSCLC who have a poor prognosis but for
whom adjuvant chemotherapy can be as effective as in patients with more advanced
disease.4 Therefore, identification of this subgroup is clinically important.
Many prognostic indicators, including tumor markers,5,6 pathologic factors,7-10
and genetic change,4 have been reported for patients with stage I NSCLC. Among
these indicators, tumor markers are simple to measure and can be judged as abnormal
clearly and consistently by different institutions if a cutoff value is set.
Of the tumor markers tested as prognostic factors for NSCLC, carcinoembryonic
antigen (CEA) has been demonstrated by several studies to be an independent prog-
nostic factor for patients with clinical stage I NSCLC.5,6 Preoperative CEA values,
however, have not yet been included in the staging system and do not alter the
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treatment strategy, especially in selecting patients for adju-
vant chemotherapy, either in practice or in clinical trials.
We believe that elucidating the clinicopathologic charac-
teristics of patients with stage I NSCLC showing high preop-
erative values of CEA will increase the understanding of this
poor prognostic subgroup who require treatment strategies
distinct from those for patients with stage I NSCLC.
We have two reasons for believing that high CEA values
are associated with a poor prognosis in patients with clinical
stage I NSCLC. One reason is that high preoperative CEA
values are associated with a more advanced pathologic stage
after surgery.5,11 Another reason is that high CEA values are
directly related to the tumor’s aggressive nature. To clarify
the later point, we compared the clinicopathologic character-
istics and outcomes of patients who had pathologic stage I
NSCLC and normal preoperative CEA values with those of
patients who had high CEA values before surgery but normal
levels after resection, for whom the primary tumor is thought
to be responsible for the high preoperative CEA values. In ad-
dition, we analyzed patients who had high CEA values both
before and after resection, because we anticipated that this
subgroup would have the lowest survival.
Materials and Methods
From October of 1986 to May of 2003, we measured serum CEA
levels before and after resection in 455 consecutive patients with
pathologic stage I disease who underwent complete resection for
primary NSCLC. Institutional review board approval was obtained
for collecting the data in a secure database and reporting the results
of analyses. Patients who had received preoperative chemotherapy
or radiotherapy were excluded. Stage was determined according
to the international TNM staging system.12 The histologic type of
tumor was determined using the World Health Organization classi-
fication.13
There were 277 male and 178 female patients, with a mean age of
65 years (range, 35–85 years). The histologic types were adenocar-
cinoma (n 5 313), squamous cell carcinoma (n 5 112), and others
(n 5 30). Primary tumors were classified as T1 in 301 patients and
as T2 in 154 patients. Surgical treatment was performed as follows:
pneumonectomy in 2 patients, lobectomy in 398 patients, segmen-
tectomy in 32 patients, and partial resection in 23 patients. System-
atic nodal dissection was performed in 386 patients, whereas
sampling or no resection of mediastinal or hilar lymph node was per-
formed in 69 patients for whom no node metastasis was clinically
suspected.
Serum CEA levels were measured within a 1-month period
before surgery and again 1 to 3 months after surgery. An enzyme
immunoassay method was used to measure the serum CEA level.The Journal of ThoThe cutoff value of CEA was 5.0 ng/mL according to the man-
ufacturer.
We placed patients in the N group if the preoperative CEA value
was within the normal range, in the HN group if the CEA value was
high before surgery but was normal after surgery, and in the HH
group if the CEA value was high both before and after surgery.
Four-micrometer–thick sections, including the largest piece cut
from the surface of the tumor in each case, were stained with hema-
toxylin-eosin and elastica van Gieson stains and examined by means
of light microscopy. Intratumoral blood vessel invasion (BVI) was
determined by means of the identification of tumor cells in blood
vessels. Lymphatic invasion was also morphologically distin-
guished from vascular invasion. Visceral pleural invasion (VPI)
was judged to be present if tumor cells had invaded across the vis-
ceral pleural elastic layer.
The patients were scheduled for checkups, chest radiography,
and measurement of tumor marker serum levels every 1 to 3 months
for 2 years after the operation and every 6 months thereafter. All pa-
tients except 29 were followed up until death or the last day of fol-
low-up (December 31, 2005). Of the 29 patients not followed up, 24
completed their follow-up after the 5-year anniversary of surgery.
The average length of follow-up for surviving patients was 90
months (range, 32–236 months).
We investigated the association of the CEA group with clinico-
pathologic findings and survival. The chi-square or Fisher exact test
was used to compare several clinical and pathologic factors. Sur-
vival was measured from the date of surgery until death from any
cause. Survival curves were calculated with the Kaplan–Meier
method, and differences in survival were determined by the log-
rank test. Multivariate analysis of several prognostic factors was
performed with Cox’s proportional hazards regression model. Sta-
tistical calculations were conducted with Stat View 5.0 (SAS
Institute Inc, Cary, NC).
Results
Of 455 patients with pathologic stage I NSCLC, 323 (70.9%)
were in the N group, 112 (24.6%) were in the HN group, and
20 (4.3%) were in the HH group. The patients’ clinical and
pathologic characteristics according to the CEA group are
shown in Table 1. The HN group was significantly related
to the male sex (P 5 .0014), greater age (P 5 , .0001),
smoking (P , .0001), squamous cell histology (P 5 .016),
and T2 status (P, .0001) when compared with the N group.
Adenocarcinomas in patients of the HN group were more
likely to be moderately or poorly differentiated (P ,
.0001). On the other hand, among squamous cell tumors,
the CEA group was not significantly correlated with the de-
gree of differentiation. The HN group also showed signifi-
cantly higher rates of BVI and VPI.
Figure 1, A shows survival curves according to the CEA
group. Five- and 10-year survivals were significantly lower
in the HN group (56.2% and 34.1%) and HH group (43.1%
and 24.6%) than in the N group (85.9% and 72.3%; P 5
.0001). Figure 1, B shows cancer-specific survival curves ac-
cording to the CEA group. Survivals in the HH group and the
HN group were significantly lower than that in the N group.racic and Cardiovascular Surgery c Volume 135, Number 1 45
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curves according to the CEA group and pathologic T factor.
Among patients with pathologic stage IA NSCLC, those in
the HN and HH groups showed lower 5- and 10-year sur-
vivals (62.0% and 32.3%, respectively, for the HN group
and 50.7% and 29.0%, respectively, for the HH group) than
did patients in the N group (91.7% and 82.8%: P , .0001).
Figure 3 shows survival curves according to the CEA
group and the histologic type. Survivals of the HN group
TABLE 1. Clinicopathologic characteristics of patientswith
pathologic stage I non–small cell lung cancer (n 5 455)
Characteristics Total
N
Group
HN
Group
HH
Group
P
valuez
Sex
Male 279 181 82 14 .0014
Female 178 142 30 6
Age (y)
,67 y 220 180 36 4 ,.0001
$67 y 235 143 76 16
Smoking history
Never smoker 160 137 21 2 ,.0001
Former smoker 114 81 31 2
Current smoker 181 105 60 16
Histology
Adenocarcinoma 313 237 67 9 .0166*
Well differentiated 143 125 17 1 ,.0001
Moderately differentiated 143 100 36 7
Poorly differentiated 27 12 14 1
Squamous 112 67 38 7
Well differentiated 8 6 2 0 .5771y
Moderately differentiated 89 53 30 6
Poorly differentiated 15 8 6 1
Other 30 19 7 4
Pathologic tumor status
T1 301 233 51 17 ,.0001
T2 154 90 61 3
Lymphatic invasion
No 386 280 90 16 .1054
Yes 69 43 22 4
Vascular invasion
No 310 238 62 10 .0003
Yes 145 85 50 10
Pleural invasion
No 356 270 73 13 ,.0001
Yes 99 53 39 7
Recurrence
No 367 279 77 11 .0008
Yes 80 43 29 8
Unknown 8 1 6 1
*Comparison among adenocarcinoma, squamous, and other histologic
types.
yComparison of poorly differentiated with moderately and well-differenti-
ated NSCLC.
zP value for the chi-square test for the association between the N group
and the HN group and clinicopathologic characteristics.46 The Journal of Thoracic and Cardiovascular Surgery c Januwere significantly lower than those of the N group for both
the adenocarcinoma and non-adenocarcinoma histologic
types. The 5-year survival was 46.3% for the HN group
and 73.5% for the N group (P 5 .0021) in patients with
non-adenocarcinoma histology.
Multivariate analysis revealed that greater age, non-adeno-
carcinoma histology, pleural invasion, and the CEA HN and
HH groups were independent prognostic factors (Table 2).
Figure 4 shows survival curves according to the number of
positive prognostic factors, which include histologic type,
VPI, and preoperative CEA value. We selected these prog-
nostic factors on the basis of the results of multivariate anal-
ysis. However, age was removed because older patients were
not considered suitable candidates for adjuvant chemother-
apy. The 5-year survival was low (47.2%) for patients with
Figure 1. Survival curves (A) and cancer-specific survival curves
(B) of patients with pathologic stage I NSCLC according to the CEA
groups.ary 2008
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23% of all patients with stage I NSCLC.
Discussion
It is important to identify a subgroup of patients with patho-
logic stage I NSCLC who have a poor prognosis and may
thus benefit from adjuvant chemotherapy. In general, avail-
able independent prognostic factors for this group of patients
include VPI,9,10,14,15 BVI,9,10,14 lymphatic vessel invasion,14
pathologic T factor,9,15 tumor differentiation,10 and preoper-
ative or postoperative serum tumor markers.5,6 Shimizu and
colleagues14 analyzed 1074 patients with pathologic T1 or
T2 NSCLC, including 780 patients with pathologic stage I
NSCLC, and found that age, sex, VPI, BVI, and lymphatic
invasion were independent prognostic factors. Harpole and
Figure 2. Survival curves (A) and cancer-specific survival curves
(B) of patients with pathologic stage I NSCLC according to the CEA
groups and pathologic T factor.The Journal of Thocolleagues9 investigated 271 patients with pathologic stage
I NSCLC and showed that BVI, VPI, and pathologic T factor
were independent histopathologic prognostic factors and that
angiogenesis, p53, and erbB-2 were independent molecular
prognostic factors. Ichinose and colleagues10 also demon-
strated that VPI, BVI, and tumor differentiation were inde-
pendent prognostic factors. On the basis of these results,
VPI and BVI have been established as independent patho-
logic prognostic factors for poor survival for patients with
pathologic stage I NSCLC.
Tumor markers also have been investigated as prognostic
factors because they are simple to measure and can clearly
and consistently be judged as normal or abnormal in different
institutions if a cutoff value is set. Among these tumor
markers, CEA has been demonstrated to be an independent
prognostic factor for patients with clinical stage I NSCLC.
Okada and colleagues5 analyzed 1000 patients with clinical
stage I NSCLC and found that the preoperative serum CEA
level was an independent prognostic factor. Sawabata and
colleagues6 reached the same conclusion after studying 273
patients with clinical stage I disease. However, neither study
included established pathologic prognostic factors, such as
VPI and BVI, in the multivariate analysis. In the present
study, we adjusted for these prognostic factors, as well as
for lymphatic invasion, histologic type, and smoking history,
in the multivariate analysis and found that CEA is an inde-
pendent prognostic factor.
The prognosis of the HH group has been reported to be
poorer than that of the HN group by Okada and colleagues5
and Sawabata and colleagues.6 The present study also found
that this subgroup had the poorest survival. Persistently high
CEA levels after surgery may be related to occult residual
Figure 3. Survival curves of patients with pathologic stage I
NSCLC according to the CEA group, excluding the HH group, and
histologic type.racic and Cardiovascular Surgery c Volume 135, Number 1 47
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adjuvant chemotherapy, the group population was small and
accounted for only 4.3% of patients with pathologic stage I
NSCLC in the present study. On the other hand, if high pre-
operative CEA levels normalize after surgery in patients with
n0 disease, they are likely due to the primary tumor itself.
Why is CEA-producing lung cancer associated with a poor
prognosis? CEA-producing lung cancer has been shown to
be associated with squamous cell carcinoma, moderately to
poorly differentiated adenocarcinoma, BVI, lymphatic vessel
invasion, and VPI. All of these pathologic features have been
reported to be poor prognostic factors,8-10,14-16 and many of
them have a documented association with smoking his-
tory.15,17 Fujisawa and colleagues15 demonstrated the prog-
nostic value of smoking history in patients with pathologic
stage I NSCLC. They also found that smoking history is sig-
nificantly associated with the male sex, squamous histologic
type, greater age, and pT2. Suzuki and colleagues17 showed
that smoking history is associated with moderately to poorly
differentiated adenocarcinoma. We speculate that a propor-
tion of CEA-producing lung cancers are related to lung
cancer caused by smoking.
TABLE 2. Multivariate analysis of overall survival
Variable Hazard ratio 95% CI* P value
Age
,67 y 1 Reference —
$67 y 2.909 2.016–4.198 ,.0001
Sex
Female 1 Reference —
Male 1.110 0.666–1.848 .6891
Histology
Adenocarcinoma 1 Reference —
Non-adenocarcinoma 1.652 1.139–2.397 .0082
Smoking
Never 1 Reference —
Ever 1.274 0.725–2.238 .4003
pT
T1 1 Reference —
T2 1.358 0.930–1.985 .1133
Lymphatic invasion
No 1 Reference —
Yes 1.084 0.700–1.679 .7164
Vascular invasion
No 1 Reference —
Yes 1.283 0.879–1.872 .1962
Pleural invasion
No 1 Reference —
Yes 1.827 1.280–2.608 .0009
CEA
N 1 Reference —
HN 1.922 1.364–2.707 .0002
HH 2.478 1.364–4.500 .0029
CI, Confidence interval; CEA, carcinoembryonic antigen.48 The Journal of Thoracic and Cardiovascular Surgery c JanuIn regard to the histologic type, we found that CEA levels
were more often elevated in squamous cell carcinoma than in
adenocarcinoma. Initially, CEA was investigated in colon
adenocarcinoma and then mainly in gastrointestinal cancer.
Therefore, some physicians may find our present results cu-
rious. However, similar results have been obtained by other
studies. In the study reported by Okada and colleagues18
CEA was elevated in 9.0% (43/473) of patients with adeno-
carcinoma and in 13.4% (25/186) of patients with squamous
cell carcinoma,16 and the survival of patients with elevated
CEA levels was significantly lower than that of patients
with normal CEA levels. Serum CEA levels have been shown
to be elevated in patients with squamous cell carcinoma of the
uterine cervix18 and esophagus.19 According to a study by
Bae and colleagues,18 CEA levels were elevated in 30.2%
in patients with stage IB2 to IIA squamous cell carcinoma
of the uterine cervix, and the recurrence rate in patients
with high CEA levels was 30.8%, which was higher than
that of patients with low CEA levels (6.7%). In our study,
the survival of the HN group was significantly lower than
that of the N group in patients with non-adenocarcinoma his-
tology. From these results, we conclude that CEA is a useful
prognostic factor for all histologic types in patients with path-
ologic stage I NSCLC.
In this study, we found that greater age, non-adenocarci-
noma histology, VPI, and CEA were poor independent prog-
nostic factors for patients with pathologic stage I NSCLC. On
the basis of these results, we propose that candidates for
adjuvant chemotherapy be selected on the basis of poor
prognosis identified with a combination of these factors other
than greater age. Older patients are not generally considered
Figure 4. Survival curves of patients with pathologic stage I
NSCLC according to the number of prognostic factors. Prognostic
factors include histology, VPI, and preoperative CEA status.ary 2008
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the patients into 3 groups according to the presence of these
3 prognostic factors. The 5-year survival of patients with 2 or
more factors was only 47.2%, and these patients accounted
for 23% of all patients with stage I NSCLC. Consequently,
these patients are thought to be good candidates for adjuvant
chemotherapy.
Conclusions
CEA, VPI, and non-adenocarcinoma histology were found to
be poor independent prognostic factors in patients with com-
pletely resected pathologic stage I NSCLC. Prospective stud-
ies are warranted to clarify the benefits of adjuvant
chemotherapy for the subgroup with a poor prognosis identi-
fied on the basis of the 3 prognostic factors in patients with
stage I NSCLC.
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